# US 2026/0091103 A1 · Novel compositions comprising terpenoid and macromolecule, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091103 A1
- Document ID: US20260091103A1
- Status: Published application
- Kind: A1
- Application number: 19/115,011
- Filed: 2022-09-26
- Published: 2026-04-02
- Earliest claimed: 2022-09-26
- Assignees: Chih-An Lin; Powin Biomedical Co., Ltd.
- Applicants: Powin Biomedical Co., Ltd.
- Inventors: CHIH-AN LIN; PO-CHENG CHU; MIN-HAN ZHAO; CHAN-CHANG HU; TZUNG-JING MING; GUO-DONG WU
- Web page: https://patentgrep.com/patent/US20260091103A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- C08L 91/00: Compositions of oils, fats or waxes; Compositions of derivatives thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 31/716: Glucans
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001153: {Wilms tumor 1 [WT1]}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61P 31/16: for influenza or rhinoviruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- C08B 37/0072: {Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates}
- C08L 5/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/575: {humoral response}
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- A61K 2039/6087: {Polysaccharides; Lipopolysaccharides [LPS]}
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2039/812: {Breast}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are novel compositions comprising oil@HA-derivative particles with high potential for the use in the stimulation of immune response. Methods to produce such compositions and methods of uses thereof in treating or preventing a disease or disorder are also provided.

## Claims

### Claim 1

A composition comprising oil and macromolecule; the oil and macromolecule together form a plurality of particles; the macromolecule comprises:
at least one first unit, wherein the first unit is a first disaccharide; and
at least one second unit, wherein the second unit is a conjugation of a second disaccharide and a hydrophobic compound;
wherein the at least one first unit and the at least one second unit are linked to each other to form the macromolecule.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the oil is a terpenoid; or
wherein the first disaccharide is composed of D-glucuronic acid and N-acetylglucosamine; or
wherein the second disaccharide is composed of D-glucuronic acid and N-acetylglucosamine; and in the second unit, the hydrophobic compound is attached to carbon 6 of the D-glucuronic acid.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the D-glucuronic acid and N-acetylglucosamine in the first disaccharide are linked by a β-(1,3) bond; or
the N-acetylglucosamine and the D-glucuronic acid in the second disaccharide are linked by a β-(1,3) bond;
or the at least the first unit and the at least the second unit are linked to each other by a β-(1,4) bond to form the macromolecule.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the macromolecule is a compound of formula (I):
and wherein A group is R—NH— or R—X—NH—; wherein R group is a hydrophobic group derived from the hydrophobic compound, X denotes a hetero-atom (such as O, S, or N), a carbonyl group, or —O—CO—C1-5 alkylene-, wherein the alkylene can be optionally substituted by one or more substituents selected from a group consisting of alkyl, aromatic, anti-aromatic, cycloalkyl, acetyl, amino, hydroxyl, and thiol groups, or an alkane or alkene group, of which the main carbon chain has carbon atom selected from one to ten, such alkane or alkene group can be optionally substituted by one or more substituents selected from a group consisting of alkyl, aromatic, anti-aromatic, cyclic group, carbonyl, acetyl, keto, amino, hydroxyl, and hetero-atom (such as O, S, or N) etc.; or —X—NH— group can be denoted as an amino acid, whose main chain has 2 to 6 carbon atoms, such as glycine, alanine, valine, leucine, isoleucine; x and y each individually represent an integer value, x≥1, y≥x, and x+y≥3; or
the particles are detectable by a particle size analyzer, a transmission electron microscope, or a scanning electron microscope.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition is an aqueous composition or an oil-in-water composition; or
the macromolecule is an amphiphilic compound and the hydrophilic-lipophilic balance value (HLB value) of the macromolecule is greater than 7.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the hydrophobic compound is selected from the group consisting of cholesterol derivatives, octadecylamine, octadecylamine derivatives, steroids, steroid derivatives, saturated or unsaturated long chain fatty amines, and saturated or unsaturated long chain fatty amine derivatives, or any combination thereof.

### Claim 7 (depends on 2)

The composition of claim 2, wherein the terpenoid is liquid or solid at room temperature; or
the terpenoid is a cyclic compound or a non-cyclic compound; or
the terpenoid consists of 1˜20 sesquiterpene(s); or
the terpenoid is an unsaturated terpenoid.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the oil is selected from the group consisting of squalene, squalane, ocimene, farnesene, and paraffin oil, or any combination thereof.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the macromolecule has an average molecular weight of at least 10 kDa and less than or equal to 1000 kDa; or
wherein in the composition, at least 70% by molar ratio of the units per macromolecule on average are the first units.

### Claim 10 (depends on 1)

The composition of claim 1, wherein in the composition, the weight ratio of the oil and the macromolecule ranges from 1:100 to 80:1; or
the weight percentages of the oil and macromolecule are respectively equal to or more than 0.01% to 40% and equal to or more than 0.001% to 3%, based on the total weight of the composition; or
at least 50% (w/w) of oil in the composition is encapsulated in the particles, based on the total content of oil in the composition being 100% by mass; or
the composition comprises at least 1% (v/v) of oil, based on the total volume of the composition.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the macromolecule is prepared by a method comprising mixing 0.0001˜2 equivalent of the hydrophobic compound with 1 equivalent of hyaluronic acid; or in the composition, the molar ratio of the first unit and the second unit per macromolecule on average ranges from 99:1 to 1:1.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising the composition of claim 1.

### Claim 13 (depends on 1)

Use of the composition or the pharmaceutical composition of claim 1 in stimulating an immune response in a subject.

### Claim 14 (depends on 1)

Use of the composition or the pharmaceutical composition of claim 1 in the treatment or prevention of a disease or disorder.

### Claim 15 (depends on 1)

A method of stimulating an immune response in a subject, comprising administering the composition or the pharmaceutical composition of claim 1 to the subject.

### Claim 16 (depends on 1)

A method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering the composition or the pharmaceutical composition of claim 1 to the subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein the disease or disorder is a tumor or cancer.

### Claim 18 (depends on 17)

The method of claim 17, wherein the tumor or cancer is a breast cancer or other solid tumor.

### Claim 19 (depends on 16)

The method of claim 16, wherein the disease or disorder is a pathogenic disease, HIV or other viral infection, fungal infection, protozoan infection, or bacterial infection.

### Claim 20 (depends on 13)

The use of claim 13, wherein pharmaceutical composition is a vaccine; or the subject is human.
